Abstract
Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Current Drug Targets
Title:Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Volume: 15 Issue: 3
Author(s): Ana C. Brett, Tatiana R. Rosenstock and A. Cristina Rego
Affiliation:
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Abstract: Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Export Options
About this article
Cite this article as:
Brett C. Ana, Rosenstock R. Tatiana and Rego Cristina A., Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/1389450114666131124140704
DOI https://dx.doi.org/10.2174/1389450114666131124140704 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efflux Pumps in Drug Resistance of Candida
Infectious Disorders - Drug Targets Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Selected Recent Advances in the Synthesis of Bioactive Compounds Using Olefin Metathesis as a Key Step
Current Organic Chemistry Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design The Overlapping Syndromes of the Pick Complex
Current Alzheimer Research Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Book Review: The New Handbook of Multisensory Processing. Barry E. Stein, ed. June 2012. The MIT Press. No. of pages 823. ISBN: 987-0-262-01712-1
Neuroscience and Biomedical Engineering (Discontinued) Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors
Current Medicinal Chemistry Psychiatric/Psychosocial Rehabilitation (PSR) in Relation to Residential Environments: Housing and Homelessness
Current Psychiatry Reviews Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry Algae Biotechnology – Green Cell-Factories on the Rise
Current Biotechnology Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Exhaled Nitric Oxide as a Potential Biomarker of Continuous Positive Airway Pressure Therapy for Severe Obstructive Sleep Apnea Patients
Current Respiratory Medicine Reviews Withdrawal Notice: A Panoramic View on the Phytochemical, Nutritional and Therapeutic value of Ziziphus mauritiana Lam.: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Perspectives of Medieval Persian Medicine on Multiple Sclerosis
Current Drug Metabolism